Formulation: A solid
Formal Name: 4-(trifluoromethoxy)-N-[[2-(trifluoromethyl)phenyl]methyl]-benzenecarboximidamide
Purity: ≥98%
Formula Markup: C16H12F6N2O
Formula Weight: 362,3
Shelf life (days): 1460
CAS Number: 305339-41-7
Notes: BZAD-01 is an antagonist of NR2B subunit-containing NMDA receptors (Ki = 72 nM).{51579} It is selective for NR2B subunit-containing NMDA receptors over those containing NR2A subunits in a calcium mobilization assay (IC50s = 47 and >10,000 nM, respectively). Oral administration of BZAD-01 reduces hyperalgesia induced by carrageenan in rats (ED50 = 5.5 mg/kg). BZAD-01 (10 mg/kg) reduces dopaminergic neuron loss in the rat substantia nigra pars compacta and improves measures of ipsilateral curling, ipsilateral head positioning, and beam walking in a rat model of Parkinson’s disease induced by the catecholaminergic neurotoxin 6-OHDA (Item No. 25330).{51578}
English
Deutsch
